🇺🇸 Tenofovir/Emtricitabine in United States

269 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Virologic Failure — 80 reports (29.74%)
  2. Drug Interaction — 33 reports (12.27%)
  3. Foetal Exposure During Pregnancy — 33 reports (12.27%)
  4. Death — 27 reports (10.04%)
  5. Drug Resistance — 19 reports (7.06%)
  6. Exposure During Pregnancy — 18 reports (6.69%)
  7. Drug Level Increased — 17 reports (6.32%)
  8. Viral Load Increased — 16 reports (5.95%)
  9. Ataxia — 13 reports (4.83%)
  10. Vomiting — 13 reports (4.83%)

Source database →

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is Tenofovir/Emtricitabine approved in United States?

Tenofovir/Emtricitabine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tenofovir/Emtricitabine in United States?

Bristol-Myers Squibb is the originator. The local marketing authorisation holder may differ — check the official source linked above.